Edkem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 6.47 Cr
as on 16-11-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16.74 Cr
as on 16-11-2024
- Revenue -2.21%
(FY 2023)
- Profit 11.67%
(FY 2023)
- Ebitda -17.69%
(FY 2023)
- Net Worth 31.17%
(FY 2023)
- Total Assets -4.56%
(FY 2023)
About Edkem Pharmaceuticals
The Corporate was formerly known as Edkem Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.50 Cr and a paid-up capital of Rs 6.47 Cr.
The company currently has active open charges totaling ₹16.74 Cr.
Jitendra Ranpara, Basant Agrawal, Ankita Agrawal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2016PLC092826
- Company No.
092826
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Edkem Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankita Agrawal  | Director | 12-Jun-2018 | Current |
| Jitendra Ranpara | Director | 23-Mar-2019 | Current |
| Basant Agrawal | Director | 06-Jul-2016 | Current |
| Santoshkumar Agrawal | Director | 06-Jul-2016 | Current |
Financial Performance of Edkem Pharmaceuticals.
Edkem Pharmaceuticals Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.21% decrease. The company also saw a substantial improvement in profitability, with a 11.67% increase in profit. The company's net worth Soared by an impressive increase of 31.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edkem Pharmaceuticals?
In 2023, Edkem Pharmaceuticals had a promoter holding of 99.07% and a public holding of 0.93%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 12 Dec 2017 | ₹8.37 Cr | Open |
Axis Bank Limited Creation Date: 08 Dec 2017 | ₹8.37 Cr | Open |
How Many Employees Work at Edkem Pharmaceuticals?
Edkem Pharmaceuticals has a workforce of 55 employees as of Sep 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edkem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edkem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
